Peptide Database

58+ comprehensive peptide profiles with mechanisms, clinical data, dosing protocols, and safety information.

Sample 12-Week Protocol Arc Dose × Time
Titration Maintenance Taper W0 W4 W8 W12 Dose level
Titration W1–4 Maintenance W4–8 Taper W8–12

11 peptide profiles · Metabolic & Weight

Metabolic & Weight

Tesofensine (Capsule)

Triple Monoamine Reuptake Inhibitor

A triple monoamine reuptake inhibitor with potent appetite suppression and weight loss effects.

Typical Dose
One capsule (per prescriber guidance)+
Evidence
Moderate Evidence
Learn More: Tesofensine (Capsule)
Metabolic & Weight

SLU-PP-332 (Capsule)

Exercise Mimetic / ERR Agonist

An ERRα/γ agonist that mimics the metabolic effects of endurance exercise at the molecular level.

Typical Dose
One capsule (per prescriber guidance)+
Evidence
Preliminary
Learn More: SLU-PP-332 (Capsule)
Metabolic & Weight

Retatrutide

Triple GIP/GLP-1/Glucagon Receptor Agonist

A triple agonist targeting GIP, GLP-1, and glucagon receptors — showing up to 24.2% weight loss in Phase II trials.

Typical Dose
1+
Evidence
Strong Evidence
Learn More: Retatrutide
Metabolic & Weight

Tirzepatide

GIP/GLP-1 Dual Receptor Agonist

The first dual GIP/GLP-1 receptor agonist, demonstrating superior weight loss outcomes compared to GLP-1 monotherapy.

Typical Dose
2.5+
Evidence
Strong Evidence
Learn More: Tirzepatide
Metabolic & Weight

Semaglutide

GLP-1 Receptor Agonist

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management with robust cardiovascular benefits.

Typical Dose
0.25+
Evidence
Strong Evidence
Learn More: Semaglutide
Metabolic & Weight

Cagrilintide

Amylin Receptor Agonist

A long-acting amylin analog that complements GLP-1 therapy for superior weight loss and metabolic control.

Typical Dose
0.16+
Evidence
Strong Evidence
Learn More: Cagrilintide
Metabolic & Weight

AOD-9604

HGH Fragment

A fragment of human growth hormone that targets fat metabolism without the growth-promoting effects of full HGH.

Typical Dose
300+
Evidence
Limited Evidence
Learn More: AOD-9604